Basel, November 13, 2026 – Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization of Cosentyx® (secukinumab) for adolescents aged 12 years and older with active moderate to severe hidradenitis suppurativa (HS) who...

Basel, Switzerland – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Gazyva®/Gazyvaro® (obinutuzumab) as an add-on therapy for the treatment of adult patients with moderate-to-severe, active, autoantibody-positive systemic lupus erythematosus (SLE) despite...

PLAINSBORO, N.J. and BAGSVÆRD, Denmark — Novo Nordisk today announced the submissions of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for etavopivat, an investigational, once-daily, orally available, selective activator of pyruvate kinase...